This study will evaluate the pharmacokinetics of ridaforolimus including the area under the concentration-time curve (AUC\[0-infinity\]) and maximum concentration (Cmax) after administration of a single dose of ridaforolimus in patients with moderate hepatic insufficiency and healthy matched control subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
19
single oral dose administration 10 mg ridaforolimus
Area Under the Curve (AUC[0-infinity]) of ridaforolimus following a single oral dose.
Time frame: 288 hours postdose
Maximum Concentration (Cmax) of ridaforolimus following a single oral dose.
Time frame: 288 hours postdose
Tmax of a Single Oral Dose of Ridaforolimus.
Time frame: 288 hours postdose
Apparent Terminal Half-life (t1/2) of a Single Oral Dose of Ridaforolimus.
Time frame: 288 hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.